Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Amwill Healthcare IPO
Price Band
₹105.0–111.0
Issue Size
₹59.98 Cr
Lot Size
1,200 shares
Min Investment
₹133,200
GMP
—
Issue Price
₹111.0
Amwill Healthcare IPO AI Summary
- Amwill Healthcare IPO is listed on BSE SME.
- Price band: ₹105.0–₹111.0 per share, lot size 1,200 shares (min. investment ₹133,200).
- Subscription window: 05 Feb–07 Feb 2025, listing on 12 Feb 2025.
Amwill Healthcare Limited is a growing player in the derma-cosmetic sector with a focus on dermatological solutions. The company has shown revenue growth in recent years, although the latest figures reflect a decrease in total income for the most recent 9-month period. The IPO aims to raise funds for working capital, marketing, and other corporate purposes.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Amwill Healthcare IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 07 Feb 2025 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Amwill Healthcare IPO Grey Market Premium (GMP) Today
GMP not available yet
Grey Market Premium is updated daily. Check back closer to the listing date.
About the Company
Incorporated in August 2017, Amwill Health Care Limited is a derma-cosmetic development firm that collaborates with contract manufacturers, distributors, and third-party product development agencies. This collaboration has enhanced the company's manufacturing, packaging, and distribution capabilities. The product portfolio of the Company is divided into two categories, namely, Development of generic dermatological solutions and Formulating targeted solutions for dermatological issues. The company markets its products in Karnataka, Andhra Pradesh, and Telangana, focusing on strengthening its presence before entering new markets to build a customer base. The company develops products for dermatological disorders, including acne, fungal infections, anti-aging, histaminic, periorbital hyperpigmentation, scabies, perspiration, trichology, and vitiligo. As of September 30, 2024, the company has 84 employees on payroll. Competitive Strength Extensive product portfolio supported by product formulation capabilities Provision of high-quality product development through tie-ups with contract manufacturers and prototype developers Well-experienced management team with proven project management and implementation skills Asset-light business model.
Company Financials (₹ Cr)
As of 2024-09-30
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 28.89 | 18.98 | 12.39 | 6.59 |
| Total Income | 23.25 | 44.28 | 30.28 | 27.62 |
| Profit After Tax | 6.52 | 12.54 | 3.11 | 2.57 |
| NET Worth | 23.68 | 17.16 | 4.60 | 1.49 |
| Reserves and Surplus | 8.08 | 17.11 | 4.57 | 1.46 |
Key Ratios
EPS
₹8.04
NAV
₹11.00
ROE
73.06%
ROCE
94.16%
RoNW
73.06%
P/B Value
10.09
P/E Ratio
13.81
Market Cap
₹222.04 Cr
PAT Margin
28.53%
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Trident Lifeline Ltd | 45.81 | 13.37% | 45.06 | 6.13 | 6.13 |
| Vaishali Pharma Limited | 39.97 | 1.68% | 26.45 | 0.68 | 0.64 |
| Amwill Healthcare Limited This IPO | 11 | 73.06% | — | 8.04 | 8.04 |
Promoters
Tarun Gandhi
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Funding of Working Capital Requirement of the company 25.00 2 Marketing and brand building activities 5.00 3 General Corporate Purposes 14.24 4 Issue expenses 5.70 Total 49.93
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹27.62 Cr in the year ending March 31, 2022, increasing to ₹30.28 Cr by March 31, 2023, then rising further to ₹44.28 Cr in the year ending March 31, 2024. However, total income decreased to ₹23.25 Cr as of September 30, 2024, though this is a 9-month figure, not a full year, so isn't directly comparable.
Profit Trend
Profit After Tax was ₹2.57 Cr in the year ending March 31, 2022, growing to ₹3.11 Cr by March 31, 2023, and then increasing to ₹12.54 Cr in the year ending March 31, 2024. As of September 30, 2024, profit after tax was ₹6.52 Cr, though this is a 9-month figure, not a full year, so isn't directly comparable.
Valuation
Amwill Healthcare's implied P/E at the issue price is approximately 13.81, which is lower than its peers, with P/E ratios ranging from 26.45 to 45.06.
Grey Market Premium, Explained
The Grey Market Premium (GMP) is an unofficial indicator of the likely listing price of an IPO. It reflects the demand for the shares in the grey market before they are officially listed. A positive GMP suggests strong demand, while a negative GMP indicates weaker demand.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment strategy and risk tolerance. It's important to consider the company's growth potential and market conditions.
Who May Want to Wait
Investors who are risk-averse or prefer stable, established companies may want to avoid IPOs like this, which can be subject to market fluctuations and uncertainties.
IPO Timeline, Explained
The IPO process involves several key dates: the opening date for subscription is February 5, 2025, and the closing date is February 7, 2025. Allotment of shares will be finalized by February 10, 2025, and the listing date is set for February 12, 2025.
Listing Gains — The Risk
Listing gains refer to the potential profit an investor can make when shares are listed on the stock exchange and sold at a higher price than the issue price. However, these gains are not guaranteed and can be influenced by market conditions, investor sentiment, and the company's performance post-listing.
This evaluation is generated from Amwill Healthcare's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is the price band of Amwill Healthcare IPO?
The price band of Amwill Healthcare IPO is ₹105.0–₹111.0 per share.
When does Amwill Healthcare IPO open and close?
Amwill Healthcare IPO opens on 05 February 2025 and closes on 07 February 2025.
When does Amwill Healthcare IPO list on the stock exchange?
Amwill Healthcare IPO listed on 12 February 2025 at ₹111.0.
What is the lot size for Amwill Healthcare IPO?
The lot size for Amwill Healthcare IPO is 1200 shares, requiring a minimum investment of ₹133,200.
What is the issue price of Amwill Healthcare's IPO?
The issue price is ₹111.0.
What is the minimum investment required?
The minimum investment required is ₹133,200.0.
What is the lot size for the IPO?
The lot size is 1200 shares.
When is the IPO open for subscription?
The IPO is open for subscription from February 5, 2025, to February 7, 2025.
When will the shares be listed?
The shares are expected to be listed on February 12, 2025.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
05 Feb 2025
Close
07 Feb 2025
Allotment
10 Feb 2025
Listing
12 Feb 2025
Similar IPOs
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Amwill Healthcare?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.